Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Cardio-Oncology

Fig. 1

From: Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy

Fig. 1

Kaplan Meier Survival Curves Comparing 1 Year Overall Survival Patients Experiencing Myocarditis and Pericardial diseases. A represents myocarditis patients (n = 424) and matched non-myocarditis patients (HR:1.26, 95% CI:1.04–1.54, p = 0.02). B represents pericardial disease patients and matched non-pericardial disease patients (n = 3,945, HR:1.46, 95% CI:1.37–1.56, p < 0.0001). A.O. and M.S. conceived and designed the study; A.O., M.S., and H.H acquired and performed data analysis; A.O, M.S, H.H, M.N., B.L., J.D., A.N., N.N., Y.Z., and P.P. interpreted the results, drafted, and revised the final manuscript

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us